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INTRODUCTION
Synaptic pathology plays a critical role in Alzheimer's disease (AD) 1, 2 and correlates with cognitive decline. [3] [4] [5] [6] Because "synapse failure" is increasingly recognized as a hallmark of AD, 7 synaptic markers hold promise for the diagnosis and monitoring of this condition. Neurogranina postsynaptic protein mainly localized into dendritic spines of neurons within associative cortical areas [8] [9] [10] -is involved in synaptic plasticity. 11 Neurogranin expression is significantly lower in the cortex and hippocampus of post-mortem AD brains versus controls. 2, 12 Compared with healthy controls (HCs), CSF neurogranin concentrations are increased in AD 13 and mild cognitive impairment (MCI) converting into AD (MCI-AD). [14] [15] [16] Moreover, neurogranin predicts MCI to AD dementia progression, 14, 17, 18 and the rate of cognitive decline, 14 and correlates longitudinally with hippocampal atrophy rates, 17, 19 as well as with future reduction in cortical glucose metabolism assessed by 18 F-Fluorodeoxyglucose-PET ( 18 F-FDG-PET). 17 Herein, we investigated the diagnostic accuracy of CSF neurogranin in distinguishing clinical AD dementia patients from HCs and frontotemporal dementia (FTD) patients. Furthermore, we examined neurogranin diagnostic accuracy across the spectrum of AD pathology using an unbiased descriptive categorization system, the "A/T/N" scheme, based on core AD biomarkers and independent of cognitive impairment severity. 20 It includes three biomarker categories reflecting AD pathophysiology, where "A" refers to amyloid-beta (Aβ) pathology, "T" to tau pathology, and "N" to neurodegeneration.
To this end, we tested whether CSF neurogranin distinguished HCs from I) AD pathology patients (presenting decreased CSF concentrations of Aβ1-42 peptide and increased amounts of total tau (t-tau) or hyperphosphorylated tau (p-tau) protein), 21 II) patients showing tau pathology only, and III) patients with Aβ pathology only.
We also assessed the ability of neurogranin to discriminate AD pathology from FTD.
MATERIALS AND METHODS

Standard protocol approvals, registrations, and patient consents
The study was conducted in accordance with the tenets of the Declaration of Helsinki and was approved by the local Ethical Committees at each participant university. All participants or their representatives gave written informed consent for the use of their clinical data for research purposes.
Study participants
The research was designed as a multicentre cross-sectional study retrospectively conducted in a convenience series from three independent European academic AD research centres and 
Patient stratification
Categorization according to the clinical diagnostic approach ("Level I")
The clinical diagnosis of AD dementia was performed according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) consensus criteria. 22 The clinical diagnosis of MCI was based on MCI core clinical criteria. 23 The diagnosis of the FTD was performed according to the consensus on clinical diagnostic criteria of 1998. 24 HCs were individuals who I) volunteered for a lumbar puncture, II) showed a negative history of neurological or psychiatric diseases, and III) had a Mental-State Examination (MMSE) score between 27 and 30.
Of the 23 cognitively HCs (first group), two individuals from the Gothenburg cohort showed CSF t-tau concentrations higher than the established cut-off value. Being asymptomatic-at-risk of AD 21 or preclinical AD. 25 they were excluded from further analyses. The second group consisted of 41 clinically defined MCI cases. 23 The third and fourth groups included 35 AD patients 21 and 9 FTD patients, respectively (Figure 1 ). 24 Categorization following the A/T/N system ("Level II") AD and MCI patient classification followed the biomarker-based descriptive stratification model ("A/T/N" system) recently proposed by Jack and colleagues. 20 26 or MCI due to AD cases, 23 all showing positivity to both Aβ and tau markers. Finally, the FTD participants (n = 9) (Group 6) included seven patients who were both Aβ1-42 and tau-negative, one patient who was Aβ1-42 negative and tau positive, and one patient who was Aβ1-42-positive and tau-negative. According to the IWG-2 criteria, the latter participant should be defined as a case of FTD and not as a patient with a frontal variant of AD. 21 Of note, since the A/T/N system is not directly applicable to FTD, this last group (VI) was examined exclusively in terms of clinical diagnosis (Figure 1 ).
CSF sampling
A diagnostic lumbar puncture was performed in all participants. All CSF samples included in the three study cohorts were collected in polypropylene tubes, centrifuged at 1000 g for 10 min
at +4°C (samples collected at IM2A in Paris), 1500 g for 10 min at +4°C (samples collected at DZNE in Rostock), 1800 g for 10 min at +4°C (samples collected at Mölndal Clinical Neurochemistry Laboratory). The collected supernatant was aliquoted and stored at -80°C pending biochemical analysis.
Immunoassays for CSF core biomarkers
For the Paris cohort, CSF analyses of Aβ1-42, t-tau, p-tau were performed at the Laboratory of INNOTEST hTAU-Ag, 28 and INNOTEST Phospho- Tau[181P] 29 (Fujirebio Europe NV, Gent, Belgium), respectively. All analyses were performed by board-certified laboratory technicians blinded to clinical information. CSF biomarkers abnormalities were defined based on reference values currently utilized in each memory clinic: at IM2A in Paris, Aβ1-42 <500 pg/mL, t-tau >450 pg/mL, p-tau181 >60 pg/mL; at DZNE in Rostock, Aβ1-42 <567 pg/mL, t-tau >512 pg/mL, p-tau181 >66 pg/mL for the CSF samples measured before 06/2012 and Aβ1-42 <450 pg/mL, t-tau >450 pg/mL, p-tau181 >62 pg/mL for the CSF samples measured after 06/2012; at Mölndal Clinical Neurochemistry Laboratory, Aβ1-42 <550 pg/mL, t-tau >400 pg/mL, p-tau181 >80 pg/mL.
Immunoassay for CSF neurogranin
All CSF neurogranin analyses were performed at the Clinical Neurochemistry Laboratory at the Sahlgrenska University Hospital, Mölndal, Sweden. We used the same methodology as the one employed in a previous study. 14 In short, CSF neurogranin was measured using an in-house ELISA assay based on the monoclonal antibody Ng7 (epitope including amino acids 52-65 on neurogranin) for capture, a polyclonal neurogranin anti-rabbit antibody (ab23570; Upstate Biotechnology, Lake Placid, NY, USA) for detection, and full-length neurogranin protein as calibrator. All analyses were performed on one occasion with randomized samples using one batch of reagents by board-certified laboratory technicians blinded to clinical information to avoid bias.
Statistical Analysis
The associations of diagnostic groups with sex and age were assessed with Fisher's exact tests and nonparametric Kruskal-Wallis (KW) tests, respectively. All neurogranin values were initially adjusted for age, sex, and site using nonparametric regression. This step allowed age-, sex-, and site-independent assessment of the diagnostic potential of neurogranin while foregoing assumptions of normality. Whenever the result of the KW test was statistically significant (P < 0.05), post-hoc groupwise comparisons of neurogranin values were performed with the Conover's test for multiple comparisons. Results of post-hoc testing were corrected for multiple comparisons using a False Discovery Rate (FDR) procedure (α = 0.05). We then evaluated the diagnostic potential of neurogranin using logistic regression within a Leave-One-Out Cross-
Validation (LOO-CV) approach in the following a priori comparisons: AD versus HCs, AD versus FTD, in Level I of categorization; HCs versus [A-/T±/N+, A-/T+/N±], HCs versus [A+/T-/N-], HCs versus [A+/T±/N+, A+/T+/N±], and [A+/T±/N+, A+/T+/N±] versus FTD, in
Level II. In this analysis, age-, sex-, and site-adjusted neurogranin values were entered as predictors and the diagnostic group was entered as the dependent variable. After model fitting, we calculated the area under the receiver operating characteristic (AUROC) curve by pooling predictions computed on the test sets from each train-test split in the LOO-CV procedure.
Successively we computed its associated confidence intervals using a bootstrap procedure package. 33 Two-tailed P values < 0.05 were considered statistically significant. Table 1 summarizes the levels of all analytes, combined with demographic and clinical data of the population classified according to Level I. Compared with HCs, CSF neurogranin levels were significantly increased in AD patients (P = 0.004). Higher CSF neurogranin levels were observed in AD group (P = 0.004) compared with FTD group (Figure 2A) . These two groups also presented markedly higher CSF neurogranin concentrations compared with cases negative for all the core biomarkers [A-/T-/N-] (P < 0.001 for both groups), those who were Aβ-positive only [A+/T-/N-] (P < 0.001 for both groups), and FTD patients (P < 0.001 for both groups) ( Figure 2B ).
RESULTS
CSF neurogranin concentrations (Level I)
CSF neurogranin concentrations (Level II)
Diagnostic accuracy of neurogranin (Level I)
We found that CSF neurogranin was able to differentiate HCs from AD dementia patients with an AUROC of 0.72 (95% CI, 0.58-0.86) ( Figure 3A ). CSF neurogranin was also able to discriminate AD from FTD with an AUROC of 0.76 (95% CI, 0.55-0.96) ( Figure 3B ).
Diagnostic accuracy of neurogranin (Level II)
We found that CSF neurogranin was able to differentiate cognitively HCs from 
DISCUSSION
Results of Level I (Figure 2A ) are consistent with previous reports showing increased CSF neurogranin levels in AD dementia patients versus HCs. [14] [15] [16] [17] [18] [19] 34, 35 . Increased CSF neurogranin concentrations in AD dementia are most likely caused by the extracellular release of synaptic proteins resulting from synaptic dysfunction and loss. Interestingly, higher CSF neurogranin concentrations were found in AD dementia versus FTD, suggesting a potential role for neurogranin in discriminating between the two forms of dementia, in line with a prior study. 34 To corroborate the increase of CSF neurogranin as an AD-specific characteristic, 35 future analyses are needed across a range of different neurodegenerative diseases.
In Level II, the significantly elevated CSF neurogranin expression detected in all patient categories displaying tau pathology ( Figure 2B ) confirms the previously observed association between neurogranin and markers of neuronal injury. 13, 14, [16] [17] [18] 35 Increased amounts of CSF t-tau and other neuronal proteins in AD reflect extensive cortical neuro-axonal degeneration. Owing to the correlation between CSF neurogranin and tau levels, higher neurogranin concentrations may serve as a proxy for the cortical synaptic degeneration occurring in AD. 2, 36 ROC curves, computed in a LOO-CV setting, were used to examine the accuracy of neurogranin as an AD diagnostic marker. In Level I, the performances of CSF neurogranin in discriminating clinical AD dementia from HCs and FTD were both fair (AUROC 0.72 and 0.76, respectively) ( Figures 3A and 3B) . In Level II, the performances in distinguishing patients with AD pathology (i.e. exhibiting positivity to both Aβ and tau markers) from HCs as well as from FTD were good (AUROC 0.85 for both comparisons) (Figures 3E and 3F) . Consequently, neurogranin delivers a higher diagnostic accuracy when the A/T/N classification system (rather than clinical criteria) is used. A fair AUROC (0.77) was found for tau positive patients versus HCs ( Figure 3C ), whereas the ability to discriminate between patients who were Aβ-positive only and HCs was unsatisfactory (AUROC 0.55) ( Figure 3D ). These results suggest that CSF neurogranin concentrations may reflect mostly tau pathology rather than Aβ pathology. 14, 18, 35 Differently from the case of tau markers, the link between CSF Aβ and neurogranin appears relatively weak and the association between amyloid plaque load and synaptic depletion appears very low if not absent at all. 14, 18, 35 Accordingly, Aβ is involved in the initial steps of AD pathophysiology rather than in synaptic loss.
37
Some potential caveats of this study merit comment. Owing to the relatively small sample size, it was not possible to divide our patients in all groups established by the original A/T/N system when Level II classification was used. 20 Because only core CSF biomarkers (and not imaging modalities) were used, MCI with AD dementia patients were grouped together for the purpose of analysis (Figure 1) . Notably, the clinical distinction between MCI and dementia might be problematic and time-dependent; accordingly, the IWG-2 criteria define MCI with AD pathology as AD in its prodromal stage. 21 Owing to the cross-sectional nature of the study, it was not possible to differentiate stable-MCI cases from those converting into dementia. Further studies are needed to confirm the potential value of neurogranin in predicting MCI to AD conversion. 17, 18 Extensive psychometric data were not available in our study, preventing the study of CSF neurogranin levels in relation to different cognitive dimensions. Moreover, the quantification of core AD CSF biomarkers was not performed in a centralized manner, potentially being subject to inter-and intra-operator variability. This study is largely exploratory as it represents the first attempt of utilizing neurogranin as a CSF biomarker for AD diagnosis in a clinical setting by applying an original, unbiased biomarker-based model of stratification 20 ) (Figure 1) . Notably, the A/T/N dissection system addresses the need for a unifying conceptual approach to biomarkers employed in AD research. In fact, given its substantially unbiased descriptive nature which eludes disease labels, the A/T/N scheme could potentially be employed in any framework of existing and upcoming diagnostic criteria. Moreover, it could be, at some point, expanded to integrate key biomarkers of other relevant proteinopathies, genetic or epigenetic factors, 38 and indicators of other pathologies such as cerebrovascular diseases or white matter pathologies which appear to impair cognitive function. 39 Finally, the multicenter design of the study may introduce variation + a comment on how we dealt with this (if we did;
please feel free to disregard this comment if it is hard to meet it…).
In conclusion, our cross-sectional study confirms and expands previous findings on the role of CSF neurogranin as a biomarker that consistently distinguishes both AD dementia patients from HCs. Because neurogranin helps discriminate AD from FTD, its increased CSF concentration seems to be AD-specific. Furthermore, the A/T/N system allows improving
